ACST Acasti Pharma Inc.

1.91
+0.16  (+9%)
Previous Close 1.75
Open 1.8
Price To Book 15.92
Market Cap 162,001,893
Shares 82,683,424
Volume 1,804,606
Short Ratio
Av. Daily Volume 2,465,314

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data due in December 2019 (1) and January 2020 (2).
CaPre (TRILOGY 1 and 2)
Hypertriglyceridemia

Latest News

  1. Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2020
  2. Acasti Pharma Co-Founder, Chief Operating and Scientific Officer to Participate on Lipid Panel at the 2019 BTIG Biotechnology Conference
  3. Acasti Pharma Schedules First Quarter Fiscal 2020 Conference Call
  4. Acasti Pharma Comments on Trading Activity and Reaffirms No Plans to Raise Capital
  5. Bausch Gains 38.9% YTD on Product Launches & Debt Reduction
  6. Acasti Pharma Trades Higher Despite 'Material Uncertainty'
  7. Acasti Pharma, Inc. to Host Earnings Call
  8. Acasti Pharma Provides Fiscal 2019 Year-End Business Update
  9. Acasti Pharma Awarded Notice of Allowance for a Second Patent in China Covering CaPre’s Omega-3 Phospholipid Composition
  10. Acasti Pharma Announces TRILOGY 2 Trial Has Achieved its 100% Patient Randomization Target in Patients with Severe Hypertriglyceridemia
  11. Acasti Issues Shares in Settlement of Claims with Former Chief Executive Officer
  12. Acasti Pharma to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
  13. Acasti Pharma Awarded Notices of Allowance for Additional Composition & Use Patents in Mexico, Chile and Israel
  14. Acasti Settles Claims with Former Chief Executive Officer
  15. Acasti Pharma CEO to Present at the ThinkEquity Conference on May 2nd in New York City
  16. Acasti Pharma Announces TRILOGY 1 Trial Has Achieved 100% Patient Randomization in Patients with Severe Hypertriglyceridemia
  17. Acasti Pharma Announces Publication of CaPre Bioavailability Study in Leading Peer-Reviewed Journal
  18. Acasti Pharma to Present at the 2019 Spring Investor Summit in New York City on April 2nd
  19. Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19th
  20. Acasti Pharma Recognized in TSX Venture Exchange’s 2019 Venture 50